Want to see AU:LDX full AI Analyst Report?
Top Page
Lumos Diagnostics Holdings Ltd.
(Sydney:LDX)
Select Model
Select Model
Rating:51Neutral
Price Target:
AU$0.11
▼(-66.88% Downside)
Action:Reiterated
Date:08/27/26
The score is held back most by weak financial performance (ongoing losses, negative free cash flow, and the FY2026 negative gross profit issue) and bearish technical momentum. These are partially offset by a comparatively strong earnings-call outlook centered on the PHASE agreement, reimbursement progress, and improving cash discipline, while valuation remains constrained by negative earnings and no dividend support.
Positive Factors
Long-term U.S. distribution growth opportunity
The exclusive PHASE agreement provides a multi-year commercial pathway for FebriDx, improving market access and revenue visibility. Its minimum sales commitment could support scale, customer adoption and manufacturing utilisation if regulatory clearance is obtained.
Negative Factors
Persistent unprofitability
Continued operating and net losses show that the business has not yet achieved sustainable profitability. The FY2026 negative gross profit is especially concerning because it raises questions about product economics, accounting impacts and the durability of future margins.
Read all positive and negative factors
Positive Factors
Negative Factors
Long-term U.S. distribution growth opportunity
The exclusive PHASE agreement provides a multi-year commercial pathway for FebriDx, improving market access and revenue visibility. Its minimum sales commitment could support scale, customer adoption and manufacturing utilisation if regulatory clearance is obtained.
Read all positive factors
Lumos Diagnostics Holdings Ltd. (LDX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$94.48M
Dividend YieldN/A
Average Volume (3M)5.63M
Price to Earnings (P/E)―
Beta (1Y)2.04
Revenue Growth1.36%
EPS Growth39.13%
CountryAU
Employees29
SectorHealthcare
Sector Strength45
IndustryMedical - Specialties
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding944,820,400
10 Day Avg. Volume3,659,446
30 Day Avg. Volume5,628,467
Financial Highlights & Ratios
PEG Ratio-0.88
Price to Book (P/B)3.00
Price to Sales (P/S)9.84
P/FCF Ratio-32.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.25Price Target Upside-21.88% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$30.15M
Lumos Diagnostics Holdings Ltd. Business Overview & Revenue Model
Company Description
Lumos Diagnostics Holdings Ltd. (LDX) is a diagnostics company focused on developing and commercialising point-of-care (rapid) diagnostic tests, including antigen-based tests that use immunoassay technologies. The company operates in the in-vitro ...
How the Company Makes Money
null...
Lumos Diagnostics Holdings Ltd. Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Mar 04, 2027
Earnings Call Sentiment Positive
The call was broadly positive: management secured a material exclusive U.S. distribution agreement (USD 317M minimum), completed and submitted the CLIA waiver study while expressing near-term optimism about approval, achieved strong product revenue growth and high gross margins, and materially improved cash flow and adjusted EBITDA versus prior years. Key risks remain including an outstanding CLIA waiver approval (which drives the commercial ramp), continued adjusted EBITDA losses, declines in IP/services revenue timing, and the need for incremental manufacturing capacity and near-term financing actions. Overall, the highlights (large distribution deal, reimbursement, margin improvement, improved cash flow, nondilutive funding and product momentum) outweigh the lowlights tied mainly to timing, conditionality of the waiver, and continued operating losses.Positive Updates
Secured Major U.S. Distribution Agreement (PHASE)
Signed a 6-year exclusive U.S. distribution agreement for FebriDx with PHASE Scientific that guarantees a minimum of USD 317 million in sales to Lumos over the term; PHASE also paid a USD 1.0 million exclusivity fee recognized in H1 revenue.
Negative Updates
Adjusted EBITDA Still Negative
Adjusted EBITDA loss of USD 1.4 million in H1, so the company remains unprofitable on an adjusted basis despite improvement versus FY24, with ongoing OpEx increases related to trials and U.S. commercial scaling.
Read all updates
Q2-2026 Updates
Positive
Negative
Secured Major U.S. Distribution Agreement (PHASE)
Signed a 6-year exclusive U.S. distribution agreement for FebriDx with PHASE Scientific that guarantees a minimum of USD 317 million in sales to Lumos over the term; PHASE also paid a USD 1.0 million exclusivity fee recognized in H1 revenue.
Read all positive updates
Company Guidance
Management guided that CLIA‑waiver for FebriDx is expected imminently (targeted in March), which would activate the 6‑year U.S. exclusive PHASE distribution deal guaranteeing a minimum USD 317 million in sales to Lumos (PHASE paid a USD 1.0m exclusivity fee in H1 and is expected to prepay USD 5.0m on waiver), and highlighted that FebriDx has Medicare/MAC reimbursement of USD 41.38 per test (seven MACs agreed); BARDA‑funded pediatric work (~USD 6.2m) should add ~20% to the addressable market with the pediatric trial expected to finish by year‑end. Financial guidance reinforced H1 FY26 results: revenue USD 6.1m (products USD 1.7m vs USD 0.8m prior, services USD 4.4m vs USD 5.5m), IP revenue USD 1.0m (vs 2.6m), gross profit USD 4.2m and 68% gross margin, adjusted EBITDA loss USD 1.4m (improved from a USD 4.2m loss in H1 FY24), operating cash flow +USD 0.1m (vs -6.8m), BARDA receipts USD 2.8m, and liquidity support with USD 1.0m drawn on a finance facility (USD 4.0m remaining); management said current manufacturing capacity can meet expected PHASE demand for the first two years but will require investment to scale thereafter.Lumos Diagnostics Holdings Ltd. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
46
Neutral
Cash Flow
40
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 13.48M | 12.50M | 11.13M | 10.54M | 11.63M |
| Gross Profit | -7.91M | 7.91M | 7.10M | 5.32M | 4.46M |
| EBITDA | -11.84M | -4.63M | -5.44M | -4.93M | -25.67M |
| Net Income | -5.06M | -7.18M | -8.59M | -8.97M | -45.72M |
Balance Sheet | |||||
| Total Assets | 40.74M | 20.81M | 26.84M | 25.42M | 36.94M |
| Cash, Cash Equivalents and Short-Term Investments | 15.42M | 1.96M | 6.48M | 3.02M | 7.98M |
| Total Debt | 5.94M | 6.99M | 8.06M | 9.79M | 7.19M |
| Total Liabilities | 17.88M | 14.65M | 19.73M | 15.92M | 19.05M |
| Stockholders Equity | 22.85M | 6.16M | 7.11M | 9.50M | 17.89M |
Cash Flow | |||||
| Free Cash Flow | -1.56M | -9.39M | 848.00K | -9.79M | -22.39M |
| Operating Cash Flow | 1.04M | -9.33M | 946.00K | -9.64M | -18.04M |
| Investing Cash Flow | -2.59M | -53.00K | -98.00K | 4.31M | -4.36M |
| Financing Cash Flow | 15.56M | 5.28M | 2.63M | 652.00K | -10.92M |
Lumos Diagnostics Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | AU$10.10B | 16.28 | 7.20% | 4.99% | 15.53% | 15.11% | |
54 Neutral | AU$553.96M | 23.79 | 15.80% | 5.42% | -0.90% | -25.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$94.48M | -5.88 | -164.12% | ― | 1.36% | 39.13% | |
47 Neutral | AU$18.17M | -1.35 | -35.10% | ― | -9.10% | 31.75% | |
41 Neutral | AU$19.17M | -3.12 | -164.22% | ― | ― | 26.04% |
* Healthcare Sector Average
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.11
-0.04
-25.00%
AU:BDX
BCAL Diagnostics Limited
0.06
<0.01
3.33%
AU:GSS
Genetic Signatures Ltd.
0.08
-0.22
-72.33%
AU:SHL
Sonic Healthcare Limited
20.06
-2.76
-12.11%
AU:ACL
Australian Clinical Labs Ltd
2.86
0.20
7.36%
Lumos Diagnostics Holdings Ltd. Corporate Events
Lumos Diagnostics Files 2026 Corporate Governance Statement with ASX
Aug 26, 2026
Lumos Diagnostics Holdings Limited has lodged its corporate governance statement for the financial year ended 30 June 2026 with the ASX and made it available via its investor website. The statement outlines the extent to which the company complies...
Lumos Diagnostics’ FY26 Milestones Expand FebriDx U.S. Market to Over US$1 Billion
Aug 26, 2026
Lumos reported a landmark FY26 marked by major regulatory and commercial milestones that significantly expand the U.S. opportunity for its FebriDx test. The company secured an exclusive six-year U.S. distribution agreement with PHASE Scientific va...
Lumos Diagnostics Highlights Point-of-Care Innovation in 2026 Annual Report
Aug 26, 2026
Lumos Diagnostics’ 2026 annual report underscores its commitment to innovation in point-of-care testing, highlighting its role in delivering real-time diagnostic information at the patient’s location. By emphasizing world-leading techn...
Lumos Diagnostics Narrows Annual Loss as Revenue Grows but Going-Concern Risks Persist
Aug 26, 2026
Lumos Diagnostics Holdings Limited reported a 6.4% increase in revenue to US$13.19 million for the year ended 30 June 2026, signaling modest growth in its diagnostics business. The company’s net tangible assets per ordinary security improved...
Lumos Diagnostics to Showcase Infection-Focused POC Tech at Bioshares Summit
Aug 7, 2026
Lumos Diagnostics Holdings Ltd, a leader in rapid point-of-care diagnostic technologies, focuses on helping healthcare professionals more accurately diagnose and manage medical conditions through customized assay development, manufacturing service...
Lumos Diagnostics Expands European Reach With FebriDx Deal in Romania
Jul 30, 2026
Lumos Diagnostics has signed an exclusive distribution agreement with Romanian medical device distributor Alpha Medical for its FebriDx rapid point-of-care test. FebriDx helps clinicians differentiate bacterial infections from non-bacterial causes...
Lumos Diagnostics Updates Market on Director Doug Ward’s Increased Shareholding
Jul 28, 2026
Lumos Diagnostics Holdings Ltd has disclosed a change in the shareholdings of director Doug Ward following the issue of fully paid ordinary shares under the company’s Long Term Incentive Plan. Ward received 4,166,752 new shares on 24 July 20...
Lumos Diagnostics Issues New Shares Through Employee Option Exercises
Jul 28, 2026
Lumos Diagnostics has issued 36,821 fully paid ordinary shares following the exercise of unquoted options by an employee at a strike price of $0.0576, and a further 394,408 fully paid ordinary shares via the cashless exercise of unquoted options b...
Lumos Diagnostics Launches Investor Roadshow and Quarterly Results Webinar
Jul 27, 2026
Lumos Diagnostics has released an investor presentation ahead of a roadshow in Melbourne and Sydney, where Chair Sam Lanyon and CEO Doug Ward will brief shareholders and potential investors. The company will also host a webinar on 29 July 2026 to ...
Lumos Diagnostics FY26 Revenue Rises on FebriDx Surge Despite Services Slowdown
Jul 27, 2026
Lumos Diagnostics reported a solid full-year performance for FY26, driven by rapid expansion of its FebriDx® point-of-care diagnostic product in the U.S. market. FebriDx revenue surged 875% to US$3.9 million, largely on the back of orders fro...
Lumos Diagnostics Reports Lapse of 43,000 Performance Rights
Jul 14, 2026
Lumos Diagnostics Holdings Ltd. has notified the market that 43,000 performance rights on issue under ASX security code LDXAZ have lapsed. These rights ceased because the specified performance or vesting conditions were not met, or are no longer c...
Lumos Diagnostics Shuts Shareholder Loan as Capital Raise Leaves It Debt-Free
Jul 2, 2026
Lumos Diagnostics has closed its A$5.0 million secured loan facility with major shareholders Tenmile Ventures and Ryder Capital, established in September 2025 to provide working capital while pursuing a CLIA waiver for its FebriDx® test. The ...
Lumos Diagnostics Secures A$709,837 R&D Tax Rebate to Advance Point-of-Care Platforms
Jun 29, 2026
Lumos Diagnostics has received a cash refund of A$709,837 under the Australian Government’s Research and Development Tax Incentive for the financial year ended 30 June 2025. The rebate reflects the company’s ongoing investment in its p...
Lumos Diagnostics Director Sam Lanyon Increases Shareholding via On‑Market Purchase
Jun 25, 2026
Lumos Diagnostics has disclosed a change in the interests of director Sam Lanyon, who has increased his direct holding of fully paid ordinary shares in the company. Lanyon acquired 249,725 shares via an on‑market purchase valued at $29,967, ...
Lumos Diagnostics Seeks ASX Quotation for 15.2 Million New Shares
Jun 22, 2026
Lumos Diagnostics Holdings Limited has applied to the ASX for quotation of 15,178,000 new ordinary fully paid shares, issued on June 19, 2026. The new securities arise from the exercise or conversion of existing options or other convertible instru...
Lumos Diagnostics Director Catherine Robson Increases Indirect Shareholding
Jun 19, 2026
Lumos Diagnostics Holdings Ltd. disclosed a change in director Catherine Robson’s indirect shareholding, reflecting increased personal investment in the company. Acting through a superannuation fund structure, Robson acquired 300,000 fully p...
Lumos Diagnostics Updates Director Doug Ward’s Expanded Equity Holding
Jun 5, 2026
Lumos Diagnostics Holdings Ltd. has disclosed a change in the interests of director Doug Ward, who received 3,706,331 fully paid ordinary shares, taking his holding to 6,924,331 shares, alongside existing unlisted options and performance rights. T...
Lumos ramps up U.S. rollout of FebriDx ahead of investor briefing
Jun 4, 2026
Lumos Diagnostics is expanding the U.S. rollout of its FebriDx rapid point-of-care test, which differentiates bacterial from non-bacterial respiratory infections in about 10 minutes. The company operates in the diagnostic testing industry, offerin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.